**PROCESS VALIDATION AND REGULATORY REQUIREMENTS OF METERED-DOSE INHALERS: AN OVERVIEW**

**ASHRANI SUNIL**, **GOYAL ANJU**, **VAISHNAV RAJAT**

1Department of Pharmaceutical Quality Assurance, M. Pharma Research Scholar, B.N. Institute of Pharmaceutical Sciences, Udaipur, Rajasthan, India. 2Department of Pharmaceutical Chemistry, B.N. Institute of Pharmaceutical Sciences, Udaipur, Rajasthan, India.

Received: 05 September 2017, Revised and Accepted: 31 October 2017

The goal of the validation is to assure that quality is built into the system at every step, and not just tested for at the end. The validation activities will commonly include training on production material and operating procedures, training of people involved, and monitoring of the system while in production. Each and every doses form needs to be validated to reduce the chances of batch failures and market recalls. In case of metered-dose inhalers (MDIs) it becomes mandatory. US Food and Drug Administration defines process validation as “establishing documented evidence which provides a high degree of assurance that a specific process will consistently produce a product meeting its predetermined specifications and quality characteristics,” MDIs are known as device that is made to deliver a specific amount of aerosolized medication in the form of short burst directly to the lungs when inhaled by the patient. Furthermore, the inhalational drug delivery causes less pain and is convenient for administration. The patients of asthma, emphysema, and chronic obstructive pulmonary disease are prescribed for quicker relief. The present paper is a summary of process involved in the manufacturing of MDIs and focuses on the regulatory requirements along with their process validation.

**Keywords:** Metered-dose inhalers, Process validation, Chronic obstructive pulmonary disease, Bronchitis, etc.

© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i2.22408

**INTRODUCTION**

During the past three to four decades, the pharmaceutical industry has gone leaps and bounds in context of providing better and improved medicines to the society. In earlier seventies, the initial emphasis on concept of validation commenced across the industry globally, and the manufactured products were tested for their compliance with their pre-established specifications, but soon, it was realized that final checking was not the scientific approach, and thus, they started checking each and every step of manufacturing the product [1]. Ted Byers and Bud Loefus were the first Food and Drug Administration (FDA) officials, in the mid-1970 who had proposed the concept of validation to improve the quality of pharmaceuticals. The goal of the validation is to assure that quality is built into the system at every step, and not just tested for at the end. The validation activities will commonly include training on production material and operating procedures, training of people involved, and monitoring of the system while in production [2].

US-FDA defines process validation as “establishing documented evidence which provides a high degree of assurance that a specific process will consistently produce a product meeting its predetermined specifications and quality characteristics.” According to EMEA, Process validation can be defined as documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce a medical product meeting its predetermined specifications and quality attributes [3]. Process validation has become a legal requirement by the cGMP and other regulatory bodies.

**Types of process validation [5]**

**Prospective process validation**

It is the process validation where an experimental plan known as validation protocol is implemented before the process is put to commercial use. Most of such validation efforts require some degree of prospective testing to generate validation support data.

**Concurrent process validation**

It is the process validation which provides documented evidence that the process is in a state of control when the process is actually implemented. This is normally performed by conducting in-process quality control tests during the manufacture of each production batch.

**Retrospective process validation**

It is the process validation where data’s from previous experimentation taken from the records of the completed production batches are used to provide documented evidence that the process has been in a state of control before the request for such evidence.

**Revalidation**

Revalidation helps in providing the evidence that changes in a process and/or the process environment do not adversely affect process characteristics and product quality.
**Documentation [6,7]**

Maintaining written record of each and everything going on in the company is very important activity as per the regulatory requirement by the authorities so cGMP, US-FDA, etc., all focus on good documentation practice. It is thus important for maintaining a record in process validation. The main documents required to be maintained are enlisted below:

I. Standard operating procedure (SOP)
II. Validation master plan
III. Validation protocol
IV. Validation report.

**SOP**
The SOP is a written document which clearly includes all the processing steps of the particular tasks and acts as evidence in case of conflicts of batch failures or market complaints regarding any product.

The general format of the SOPs involves:

1. Title
2. Code
3. Objective
4. Scope
5. Definitions
6. Description
7. Safety
8. Documentation
9. Effective date, review date, and version number
10. Footer: Prepared by, reviewed by, approved by, and authorized by
11. References.

**Validation master plan**
The format and content should include:

- Introduction: Validation policy, scope, location, and schedule.
- Organizational structure: Personnel responsibilities.
- Plant/process/product description: Rational for inclusions or exclusions and extent of validation.
- Specific process considerations that are critical and those requiring extra attention.
- Key acceptance criteria.
- Documentation format.

<table>
<thead>
<tr>
<th>Type</th>
<th>Ingredient</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propellants</td>
<td>CFCs 11, 12, 114</td>
<td>60-90</td>
</tr>
<tr>
<td>Dispersing agents</td>
<td>Sorbitan trioleate</td>
<td>0.01-0.8</td>
</tr>
<tr>
<td></td>
<td>Sorbitan sesquioleate</td>
<td>0.01-0.8</td>
</tr>
<tr>
<td></td>
<td>Oleic acid</td>
<td>0.01-0.8</td>
</tr>
<tr>
<td></td>
<td>Soya lecithin</td>
<td>0.01-0.1</td>
</tr>
<tr>
<td>Cosolvents</td>
<td>Ethyl alcohol</td>
<td>2-38</td>
</tr>
<tr>
<td></td>
<td>Water</td>
<td>5-10</td>
</tr>
<tr>
<td>Antioxidants and flavors</td>
<td>Ascorbic acid</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>Saccharin</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Menthol</td>
<td>-</td>
</tr>
<tr>
<td>Antimicrobials</td>
<td>Cetylpyridinium chloride</td>
<td>-</td>
</tr>
</tbody>
</table>

MDI: Metered-dose inhalers

**Validation protocol**
The validation protocol should be numbered, signed, and dated and should contain a minimum the following information:

1. Title
2. Objective and scope
3. Responsibility
4. Protocol approval
5. Validation team
6. Product composition
7. Process flowchart
8. Manufacturing process
9. Review of equipments/utilities
10. Review of raw materials and packing materials review of analytical and batch manufacturing records
11. Review of batch quantities for validation (raw materials)
12. Review of batch quantities for validation (packing materials)
13. HSE requirements
14. Review of process parameters validation procedure
15. Sampling location
16. Documentation
17. Acceptance criteria
18. Summary
19. Conclusion.

**Validation report**
The validation report should contain the approved validation protocol, tabulated or graphical results, process monitoring (forms), and all analytical results of the validation batches. The validation report should have a conclusion that explains the manufacturing specialist's statement and opinion stability testing on all validation batches must be performed according to the protocol, according to NDA/ANDA stability plan [9].

**METERED-DOSE INHALERS (MDIS)**
The origin of inhalation therapies dates back to 40th century when in India people used to inhale the smokes of the Atropa belladonna plant for the prevention from cough. The evolution of this therapy and its effectiveness depends not only on a pharmacologically active molecule but also on the route of administration and its bioavailability [10].

MDIs therapy has become a prime therapy from the 20th century with an advantage of small pocket-sized inhaler which is easy to carry for the patients. The aerosol delivery system depends on individual patient characterization and aerosol properties, i.e. distribution of particle, particle size, airway layout nature, etc. [11].

MDI products contain therapeutically active ingredients dissolved in a propellant, a mixture of propellants, or a mixture of solvents, propellants, and/or other excipients in compact pressurized aerosol dispensers. MDIs are known as a device that is made to deliver a

<table>
<thead>
<tr>
<th>Test</th>
<th>Number of values</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inspection of attributes</td>
<td>MIL-105E</td>
<td>Appearance, identity, proper assembly</td>
</tr>
<tr>
<td>Dimensional check</td>
<td>40</td>
<td>Proper components, identity</td>
</tr>
<tr>
<td>Valve delivery (spray weights) mean, RSD</td>
<td>40</td>
<td>Meter chamber size, in use test, meter chamber variability</td>
</tr>
<tr>
<td>Valve delivery at labeled number of actuations</td>
<td>6</td>
<td>Ruggedness of multiple sprays</td>
</tr>
<tr>
<td>Weight loss (leakage)</td>
<td>12</td>
<td>Sealing capability, proper rubber sealability</td>
</tr>
<tr>
<td>Loss of prime</td>
<td>12</td>
<td>Meter chamber sealability</td>
</tr>
<tr>
<td>Particulates</td>
<td>12</td>
<td>Valve cleanliness</td>
</tr>
<tr>
<td>Extractables</td>
<td>12</td>
<td>Rubber contaminants</td>
</tr>
</tbody>
</table>
specific amount of aerosolized medication in the form of short burst directly to the lungs when inhaled by the patient [12]. They are considered superior over oral drug delivery system because inhaled beta-2 agonist bronchodilators produce a more rapid onset of action. Furthermore, the inhalational drug delivery causes less pain and is convenient for administration. The patients of asthma, emphysema, and chronic obstructive pulmonary disease are prescribed for quicker relief (Fig. 1) [13].

REGULATORY REQUIREMENTS OF QUALITY SECTION OF MDIS AS PER EUROPEAN GUIDELINES [16]

Pharmaceutical developments
- Moisture content: The test for moisture content is done and amount of moisture present is recorded to ensure stability of the product.
- Delivered dose: The test for delivered dose ensures the uniformity of dose delivered each time from the inhaler.
- Fine particle dose: The particle size distribution of the active substance is determined by impinge for fine particle dose.
- Use of spacer: When the spacer is used in some products its use should be validated and relevant information given in the summary product characters.
- Breath-actuated device: The actuated device is capable of triggering all target patient group must be demonstrated by proper data collection.
- In use performance: The product must be easy to use by normal patients without sophistication.

Fig 1: Schematic diagram of a metered-dose inhaler [14]

Fig 2: Schematic representation of manufacturing process of pressurized metered-dose inhalers [15]
• Cleaning procedure: The cleaning procedure of the device should be clearly written described.
• Description of manufacturing process: The overall data of process validation of the process that demonstrates the validity of the process should be submitted.
• Control of excipients: The toxicity and purity data of excipient must be properly described.

Control of drug product
Moisture content: The test is performed if needed.
• Delivered dose uniformity: It is done to evaluate the uniformity of delivered dose.
• Leak rate: The leak rate test is done to optimize the leak within the acceptance criteria.
• Number of deliveries per inhaler: The number of deliveries per inhaler must be appropriate to meet within the labeled amount.
• Particulate matter: The absence of any particulate matter in the product must be ensured to increase the shelf life of the product.
• Container closure system: The specification for each component of the inhaler and its compliance with the specification for limits of leachable components and extraction studies should be given.
• Stability: The test for stability includes specification test, with the exception of the identity test and leachable moisture and microbial purity.

Summary of product characteristics
• Quantitative and qualitative composition: The qualitative and quantitative composition of the product should be properly stated.
• Posology and method of administration: The direction on how to use the inhaler and also the conditions in which one can opt for MDIs must be clarified.
• Special precaution for storage: The proper storage condition must be labeled on the product also if there is any special requirement should be also there.

CONCLUSION
Validation has been proven assurance for the process efficiency and sturdiness and it is the full-fledged quality attributing tool for the pharmaceutical industries. Validation eliminates the chances of batch failures as the products are manufactured as per preoptimization of each manufacturing steps. The conventional process of testing at last stage created much problems in maintain uniformity of each batch but with the introduction of the concept of process validation, it has been easy to maintain the batch uniformity of the product along with imparting quality in them. This paper has tried to summarize the process validation and regulatory requirements of MDIs which have emerged as a newer tool for drug delivery system with easy and quick response in providing relief to the asthmatic patients.

AUTHORS CONTRIBUTION
Sunil Ashrani: Compilation of data. Dr. Anju Goyal: Reviewing and checking of the manuscript.

CONFLICTS OF INTEREST
Nil.

REFERENCES